Virtue® SEB

Virtue® SEB delivers substantial doses of Sirolimus to target  treatment sites and sustains drug release at levels well  beyond the minimum therapeutic level

Preclinical testing of the Virtue® SEB system was conducted in a porcine animal model, the most broadly accepted and widely used model for testing of interventional cardiovascular devices. Preclinical studies involving 130 pigs and over 750 distinct artery treatment sites have demonstrated Virtue SEB’s ability to deliver substantial doses of Sirolimus to target treatment sites and sustain drug release at levels well beyond the minimum therapeutic level for approximately four weeks. The data was published in the EuroIntervention Journal in 2016.1

Preclinical data demonstrates pharmacokinetics that mimic drug  release profile of known, efficacious drug-eluting stents:

Cypher is Johnson & Johnson's Sirolimus eluting stent; Xience is Abbott's Everolimus eluting stent

Moreover, preclinical studies have shown that Virtue® SEB system achieves higher arterial tissue concentrations and produce minimal migration to other cardiac tissue or organs and do not show any adverse local or systemic effect, even following multiple deliveries in a single animal (typically 10 per animal).

Cypher is Johnson & Johnson's Sirolimus eluting stent; Xience is Abbott's Everolimus eluting stent

Preclinical work has also included safety, biocompatibility, histology and particulate testing. Virtue® SEB successfully passes the critical safety metric of particulate testing.


1Juan F. Granada, et al. In vivo delivery and long-term tissue retention of nano- encapsulated sirolimus using a novel porous balloon angioplasty system. EuroIntervention 2016;12:740-747.

Have any questions?
Contact us at 917.254.4900 or info@orchestrabiomed.com